A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar
- 1 April 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (4), 965-968
- https://doi.org/10.1111/bjd.15686
Abstract
The advent of therapeutic antibodies, or biological medications, has transformed the treatment of many inflammatory diseases in dermatology. Recently, the development of biosimilars, biological drugs that are highly similar in quality, safety and efficacy to approved biologics, has changed this landscape. Although biosimilars are not identical to their reference product, they are required to have the same mechanism of action, route of administration, dosage form and strength as the reference product. This also leads to the possibility that subtle differences in the activity of these biosimilars can lead to differing clinical responses. We report the first case of a lichenoid eruption induced by a biosimilar to infliximab after switching from infliximab. Several days after initial infusion of the biosimilar, the patient developed a pruritic papulosquamous eruption that was biopsied to reveal a lichenoid drug eruption. Possible mechanisms for lichenoid drug eruptions as a result of tumour necrosis factor-a inhibitor administration are discussed, along with reasons why such a reaction may occur with a biosimilar but not the original, reference product. This case report calls attention to the unique differences between biosimilars and biological medications that a clinician should consider prior to prescribing these medications.This publication has 15 references indexed in Scilit:
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyAnnals Of The Rheumatic Diseases, 2016
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension studyAnnals Of The Rheumatic Diseases, 2016
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapyAnnals Of The Rheumatic Diseases, 2015
- Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter studyJournal of Gastroenterology and Hepatology, 2015
- Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritisModern Rheumatology, 2015
- Hypersensitivity reaction to a biosimilar insulin glargine 对甘精胰岛素生物仿制品的过敏反应Journal of Diabetes, 2015
- Lichen planus–like eruptions: An emerging side effect of tumor necrosis factor-α antagonistsJournal of the American Academy of Dermatology, 2009
- Type I interferon‐associated cytotoxic inflammation in lichen planusJournal of Cutaneous Pathology, 2006
- Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cellsBritish Journal of Dermatology, 2005
- Lichen Planus Induced by Interferon-a-2B Therapy in a Patient with Cutaneous Malignant MelanomaPublished by Medical Journals Sweden AB ,1999